Source:Hematology/Oncology Clinics of North America, Volume 31, Issue 5
Author(s): Ulrike Abramowski-Mock, Juliette M. Delhove, Waseem Qasim
Teaser
This article focuses on clinical applications of T cells transduced to express recombinant T cell receptor and chimeric antigen receptor constructs directed toward hematological malignancies, and considers newer strategies incorporating gene-editing technologies to address GvHD and host-mediated rejection. Recent data from clinical trials are reviewed, and an overview is provided of current and emerging manufacturing processes; consideration is also given to new developments in the pipeline.http://ift.tt/2faAqH9
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου